Please login to the form below

Not currently logged in
Email:
Password:

Acthar

This page shows the latest Acthar news and features for those working in and with pharma, biotech and healthcare.

Mallinckrodt files for bankruptcy protection in the US

Mallinckrodt files for bankruptcy protection in the US

In addition to resolving matters relating to the opioid litigation, the bankruptcy filing will also resolve matters related to Mallinckrodt’s Acthar (corticotropin) Gel. ... Mallinckrodt agreed to pay $260m over seven years to the federal government

Latest news

  • US piles pressure on Mallinckrodt over alleged Acthar fraud US piles pressure on Mallinckrodt over alleged Acthar fraud

    system. The complainant says that Mallinckrodt understated the rebates it was due to pay Medicaid over a period in which it raised the price of its $40, 000-per-vial Acthar ... The NDA approval was awarded to Acthar’s earlier owner Questcor, which was

  • Mallinckrodt offloads CDMO for $250m Mallinckrodt offloads CDMO for $250m

    This will likely include the active ingredient for Acthar, which the pharma company has faced criticism for due to its inflated pricing. ... US health insurer Humana recently filed a lawsuit against Mallinckrodt, alleging that it overpaid $700m for Acthar

  • Humana lawsuit targets Mallinckrodt's 'billion-dollar golden goose' Humana lawsuit targets Mallinckrodt's 'billion-dollar golden goose'

    The nonprofit allegedly used money from Mallinckrodt to provide patient assistance funds solely for Acthar. ... Over the decades, other drugs superseded Acthar in many, but not all, indications, culminating in Aventis Pharmaceuticals selling the asset to

  • Mallinckrodt pays $1.2bn for Sucampo Pharma Mallinckrodt pays $1.2bn for Sucampo Pharma

    Mallinckrodt is trying to reduce its reliance on cash cow product Acthar (corticotropin) for infantile spasms and multiple sclerosis, which brought in sales of almost $309m in the third quarter of ... Acthar’s slowdown has been attributed by the

  • Ireland's Mallinckrodt buys US regenerative medicine firm Ireland's Mallinckrodt buys US regenerative medicine firm

    Ikaria. . In the previous year it shelled out $5.6bn for Questcor Pharma - getting hold of fast-growing autoimmune and inflammatory drug Acthar (repository corticotropin injection) - and another $1.3bn for

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch table for April 2014 Deal Watch table for April 2014

    7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions.

  • Pharma deals during April 2014 Pharma deals during April 2014

    Acthar sales grew by 50% in 2013 to $761.3m and is predicted to rise to $1.9bn in 2018. Questcor also provides contract manufacturing services through its subsidiary BioVectra. ... Acthar complements Mallinckrodt's portfolio of specialty pharmaceutical

  • Pharma deals during February 2014 Pharma deals during February 2014

    in litigation over two synthetic versions of Acthar (ACTH), a corticotropin with 19 indications, many in rare diseases including infantile spasms, MS, nephrology, and rheumatology.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Questcor appoints SVP corporate strategic development Questcor appoints SVP corporate strategic development

    These moves could see it expand outside the US with its lead product HP Acthar Gel  (repository corticotropin injection), an injectable drug, which is approved by the FDA in several indications ... Development programmes that complement Acthar are also

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...